Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Phosphatidylinositol 4,5 Bisphosphate 3 Kise Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kise 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kise Catalytic Alpha Polypeptide or Serine/Threonine Protein Kise PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) - Overview
Phosphatidylinositol 4,5 Bisphosphate 3 Kise Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kise 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kise Catalytic Alpha Polypeptide or Serine/Threonine Protein Kise PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Phosphatidylinositol 4,5 Bisphosphate 3 Kise Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kise 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kise Catalytic Alpha Polypeptide or Serine/Threonine Protein Kise PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Phosphatidylinositol 4,5 Bisphosphate 3 Kise Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kise 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kise Catalytic Alpha Polypeptide or Serine/Threonine Protein Kise PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) - Companies Involved in Therapeutics Development
Adlai Nortye Biopharma Co Ltd
Advenchen Laboratories LLC
Applied Therapeutics Inc
AstraZeneca Plc
Bayer AG
Chia Tai Tianqing Pharmaceutical Group Co Ltd.
Curis Inc
Genentech Inc
GlaxoSmithKline Plc
Millennium Pharmaceuticals Inc
Novartis AG
Onconova Therapeutics Inc
Petra Pharma Corp
PIQUR Therapeutics AG
Shanghai Haihe Biopharma Co Ltd
Sichuan Sinovation Bio-technology Co Ltd
SiglRx Pharmaceuticals Inc
Sphaera Pharma Pte Ltd
Yangtze River Pharmaceutical Group
Phosphatidylinositol 4,5 Bisphosphate 3 Kise Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kise 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kise Catalytic Alpha Polypeptide or Serine/Threonine Protein Kise PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) - Drug Profiles
AL-58922 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
alpelisib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BAY-1082439 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bimiralisib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
buparlisib hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fimepinostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GDC-0077 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HHCYH-33 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NSC-765844 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
omipalisib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ON-146040 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Petra-03 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PQR-514 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
serabelisib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SF-2523 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule 2 to Inhibit PIK3CA for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit PI3K Alpha for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit PIK3CA and MTOR for Colorectal Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit PIK3CA for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Pan PI3K for Ovarian Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit PI3K Alpha for Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit PIK3CA and PIK3CG for Solid Tumors - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SN-202 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SPR-965 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
taselisib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
WX-008 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Phosphatidylinositol 4,5 Bisphosphate 3 Kise Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kise 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kise Catalytic Alpha Polypeptide or Serine/Threonine Protein Kise PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) - Dormant Products
Phosphatidylinositol 4,5 Bisphosphate 3 Kise Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kise 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kise Catalytic Alpha Polypeptide or Serine/Threonine Protein Kise PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) - Discontinued Products
Phosphatidylinositol 4,5 Bisphosphate 3 Kise Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kise 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kise Catalytic Alpha Polypeptide or Serine/Threonine Protein Kise PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) - Product Development Milestones
Featured News & Press Releases
Appendix



List of Figures


Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020


List of Tables


Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indications, H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..2), H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Products under Development by Companies, H1 2020 (Contd..4), H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by Adlai Nortye Biopharma Co Ltd, H1 2020
Pipeline by Advenchen Laboratories LLC, H1 2020
Pipeline by Applied Therapeutics Inc, H1 2020
Pipeline by AstraZeneca Plc, H1 2020
Pipeline by Bayer AG, H1 2020
Pipeline by Chia Tai Tianqing Pharmaceutical Group Co Ltd., H1 2020
Pipeline by Curis Inc, H1 2020
Pipeline by Genentech Inc, H1 2020
Pipeline by GlaxoSmithKline Plc, H1 2020
Pipeline by Millennium Pharmaceuticals Inc, H1 2020
Pipeline by Novartis AG, H1 2020
Pipeline by Onconova Therapeutics Inc, H1 2020
Pipeline by Petra Pharma Corp, H1 2020
Pipeline by PIQUR Therapeutics AG, H1 2020
Pipeline by Shanghai Haihe Biopharma Co Ltd, H1 2020
Pipeline by Sichuan Sinovation Bio-technology Co Ltd, H1 2020
Pipeline by SignalRx Pharmaceuticals Inc, H1 2020
Pipeline by Sphaera Pharma Pte Ltd, H1 2020
Pipeline by Yangtze River Pharmaceutical Group, H1 2020
Dormant Products, H1 2020
Dormant Products, H1 2020 (Contd..1), H1 2020
Dormant Products, H1 2020 (Contd..2), H1 2020
Discontinued Products, H1 2020
Discontinued Products, H1 2020 (Contd..1), H1 2020
Discontinued Products, H1 2020 (Contd..2), H1 2020